Patent Assignment
Reel/Frame 035653/0635
Assignment of Assignor's Interest
Recorded: 2015-05-13
Pages: 15
Assignor
ALCON RESEARCH, LTD.
Executed: 2015-04-20
Assignee
ARROWHEAD RESEARCH CORPORATION
225 SOUTH LAKE AVENUE, SUITE 1050, PASADENA, CALIFORNIA, 91101
Covered Properties
(47)
Rnai-Mediated Inhibition of H1F1A for Treatment of Ocular Angiogenesis
Rnai-Mediated Inhibition of HIF1A for Treatment of Ocular Angiogenesis
RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
Application:
14/566,234 →
Publication:
US US20150167002A1
RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
Application:
13/113,782 →
Publication:
US US20110257246A1
RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
Application:
11/642,016 →
Publication:
US US20070155690A1
RNAI-Mediated Inhibition of IGF1R For Treatment of Ocular Angiogenesis
Application:
12/622,007 →
RNAi-MEDIATED INHIBITION OF IGF1R FOR TREATMENT OF OCULAR ANGIOGENESIS
Application:
14/229,055 →
Publication:
US US20140364480A1
RNAi-MEDIATED INHIBITION OF IGF1R FOR TREATMENT OF OCULAR ANGIOGENESIS
Application:
11/617,899 →
Publication:
US US20070275922A1
RNAi-Mediated Inhibition of Phosphodiesterase Type 4 for Treatment of cAMP-Related Ocular Disorders
Patent:
8,673,873 →
Application:
12/580,663 →
RNAi-MEDIATED INHIBITION OF PHOSPHODIESTERASE TYPE 4 FOR TREATMENT OF cAMP-RELATED OCULAR DISORDERS
Rnai-Mediated Inhibition of Phosphodiesterase Type 4 for Treatment of Camp-Related Ocular Disorders
Application:
11/617,604 →
RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS
Application:
12/700,188 →
Publication:
US US20100166676A1
Rnai-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions
RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS
Application:
13/973,176 →
Publication:
US US20130338213A1
RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS
Rnai-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions
Rnai-Mediated Inhibition of Histamine Receptor H1-Related Conditions
Rnai-Mediated Inhibition of Histamine Receptor H1-Related Conditions
RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions
RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions
Rnai-Mediated Inhibition of Spleen Tyrosine Kinase-Related Inflammatory Conditions
RNAi-Mediated Inhibition of Spleen Tyrosine Kinase-Related Inflammatory Conditions
RNAi-MEDIATED INHIBITION OF SPLEEN TYROSINE KINASE-RELATED INFLAMMATORY CONDITIONS
RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS
Application:
12/825,552 →
Publication:
US US20100267811A1
RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS
RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS
RNAi-RELATED INHIBITION OF TNFalpha SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS
Application:
12/184,351 →
Publication:
US US20090036396A1
TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
Transferrin/Transferrin Receptor-Mediated Sirna Delivery
Patent:
7,973,019 →
Application:
12/244,027 →
Low Density Lipoprotein Receptor-Mediated Sirna Delivery
Low Density Lipoprotein Receptor-Mediated Sirna Delivery
LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
Application:
12/271,476 →
Publication:
US US20090131358A1
Rnai-Related Inhibition of Tnfa Signaling Pathway for Treatment of Glaucoma
RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA
Application:
14/484,972 →
Publication:
US US20150057336A1
RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA
Application:
12/184,403 →
Publication:
US US20090035225A1
Interfering Rna Delivery System and Uses Thereof
Interfering Rna Delivery System and Uses Thereof
Interfering Rna Delivery System and Uses Thereof
RNAi-MEDIATED INHIBITION OF CONNEXIN 43 FOR TREATMENT OF IOP-RELATED CONDITIONS
Sirna Targeting Vegfa and Methods for Treatment in Vivo
Sirna Targeting Vegfa and Methods for Treatment in Vivo
Interfering Rna Delivery System and Uses Thereof
Interfering Rna Delivery System and Uses Thereof
Application:
13/706,891 →
Publication:
US US20130178421A1
Related Assignments
(6)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
May 13, 2015
From: ALCON RESEARCH, LTD.
To: ARROWHEAD RESEARCH CORPORATION
Reel/Frame 035625/0610 →
Security Interest
Aug 7, 2024
From: ARROWHEAD PHARMACEUTICALS, INC.
To: SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT
Reel/Frame 068510/0363 →
Change of Name
Aug 12, 2024
From: ARROWHEAD RESEARCH CORPORATION
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068551/0357 →
Change of Name
Aug 12, 2024
From: ARROWHEAD RESEARCH CORPORATION
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068551/0400 →
Change of Name
Aug 12, 2024
From: ARROWHEAD RESEARCH CORPORATION
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068551/0490 →
Change of Name
Aug 12, 2024
From: ARROWHEAD RESEARCH CORPORATION
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068551/0605 →